JCR Pharma ＜4552＞ continues to decline drastically. Nomura Securities downgraded investment decisions from “buy” to “neutral,” and the target stock price was also lowered from 1800 yen to 600 yen. It is clearly stated that overseas development of new drugs will shift to a system carried out in-house, and it seems that they have determined that the accuracy of deriving new drugs has decreased. Earnings forecasts have been revised downward by anticipating a decrease in contract fee income, etc. It seems that the number of catalysts affecting stock prices will decrease for some time to come.
JCRファーマ---大幅続落、今後のカタリスト少ないとして国内証券が格下げ
JCR Pharma --- drastic decline, domestic securities downgraded due to lack of catalysts in the future
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.